Skip to content
lsd.com
CompletedPhase 1 / Phase 2

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT00302744 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Closed to entry
Status
Not accepting participants
Phase 1 / Phase 2
Phase
12
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Anxiety

    Measured over 6 months

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 70 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Have advanced-stage cancer and anxiety. * Be between the ages of 18 - 70. Note: The location for the two treatment sessions is Los Angeles, California. Treatment sessions are scheduled three to six weeks apart, and they include one overnight hospital stay both times. Exclusion Criteria: * Not have cancer that affects the central nervous system or brain function. * Have no history of major psychiatric disorder. * Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease, including untreated hypertension. * Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications (except anti-hypertensive drugs). * May take PRN benzodiazepines up to 3 days before the session. * No Prozac for the previous 5 weeks. * No medications the day of and the day after treatment sessions, except may take ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration. * No alcohol consumption the day before, the day of, and the day after a session. * Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.

Where

1 study site

FacilityCityRegionCountry
Harbor-UCLA Medical CenterTorranceCaliforniaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT00302744 on ClinicalTrials.gov →

Last updated in the registry 2025-03-13. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Indication

Recruiting in